Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Cancer Disparities Progress Report and what oncologists can do to combat them.
|Articles|March 7, 2010
- August 2009
- Volume 3
- Issue 8
Is PFS Enough for Approval?, PharmaFocus: Velcade, etc.
Author(s)Onclive Team
Key Takeaways
- Personalized treatment strategies have become central to managing lung cancer brain metastases, improving patient outcomes.
- Targeted therapies and immunotherapies offer more effective, less invasive options compared to traditional methods.
Advertisement
Articles in this issue
over 16 years ago
Treating Chemotherapy-Induced Emesisover 16 years ago
Highlights from European Hematology AssociationAdvertisement
Related to this article
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Jill Gilbert, MD, discusses the journey of lifelong learning in hematology/oncology.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
Maurie Markman, MD, discusses conflicts of interest in cancer care.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
4
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
5